The extrafollicular B cell response is a hallmark of childhood idiopathic nephrotic syndrome

Nat Commun. 2023 Nov 24;14(1):7682. doi: 10.1038/s41467-023-43504-8.

Abstract

The efficacy of the B cell-targeting drug rituximab (RTX) in childhood idiopathic nephrotic syndrome (INS) suggests that B cells may be implicated in disease pathogenesis. However, B cell characterization in children with INS remains limited. Here, using single-cell RNA sequencing, we demonstrate that a B cell transcriptional program poised for effector functions represents the major immune perturbation in blood samples from children with active INS. This transcriptional profile was associated with an extrafollicular B cell response marked by the expansion of atypical B cells (atBCs), marginal zone-like B cells, and antibody-secreting cells (ASCs). Flow cytometry of blood from 13 children with active INS and 24 healthy donors confirmed the presence of an extrafollicular B cell response denoted by the expansion of proliferating RTX-sensitive extrafollicular (CXCR5-) CD21low T-bet+ CD11c+ atBCs and short-lived T-bet+ ASCs in INS. Together, our study provides evidence for an extrafollicular origin for humoral immunity in active INS.

MeSH terms

  • B-Lymphocytes
  • Child
  • Humans
  • Nephrotic Syndrome* / drug therapy
  • Nephrotic Syndrome* / genetics
  • Rituximab / therapeutic use

Substances

  • Rituximab